Opinion|Videos|August 1, 2024
Key Considerations for Selecting IPF Treatment
Author(s)Justin Oldham, MD, MS
Decision-making factors surrounding optimal IPF treatment selection are evaluated by Justin Oldham, MD, MS.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Based on your clinical experience, what patient characteristics are considered when selecting a treatment regimen?
- What challenges are often present with current antifibrotic agents (i.e., tolerability, adverse effects)?
Advertisement
Related to this article
Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.
For all the advances in breast cancer, there remains unmet need for patients whose cancer progresses after treatment with antibody-drug conjugates (ADCs). In the final week of Breast Cancer Awareness Month, AJMC® looks at an investigational vaccine approach that could come after ADCs, offering patients a low-toxicity regimen.
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Advertisement
Advertisement
Trending on AJMC
1
Preparing for Hepatitis B Functional Cure: Jordan Feld, MD, MPH
2
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
5